FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119010338> ?p ?o ?g. }

• W2119010338 endingPage "933" @default.
• W2119010338 startingPage "929" @default.
• W2119010338 abstract "No AccessJournal of UrologyClinical Urology: Original Article1 Mar 1995Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the Bladder Peter D.J. Vegt, J. Alfred Witjes, Wim P.J. Witjes, Wim H. Doesburg, Frans M.J. Debruyne, A.P.M. van der Meijden, and E. David Crawford Peter D.J. VegtPeter D.J. Vegt More articles by this author , J. Alfred WitjesJ. Alfred Witjes More articles by this author , Wim P.J. WitjesWim P.J. Witjes More articles by this author , Wim H. DoesburgWim H. Doesburg More articles by this author , Frans M.J. DebruyneFrans M.J. Debruyne More articles by this author , A.P.M. van der MeijdenA.P.M. van der Meijden More articles by this author , and E. David CrawfordE. David Crawford More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67606-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ. The followup (or time in study) varied from 2 to 81 months (mean 36 months). After complete transurethral resection of all visible tumors the patients were treated with 30 mg. mitomycin C once a week for 4 consecutive weeks and thereafter every month for a total of 6 months, and 5 x 108 colony-forming units Tice BCG or RIVM-BCG once a week for 6 consecutive weeks. For papillary tumors mitomycin C and RIVM-BCG treatments were equally effective (p = 0.53), and mitomycin C was more effective than Tice BCG therapy (p = 0.01). References 1 : Use of intravesical bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Urol. Int.1990; 45: 129. Google Scholar 2 : Bladder cancer immunotherapy. J. Urol.1982; 128: 931. Link, Google Scholar 3 : Treatment of superficial bladder cancer with intravesical BCG. In: Immunotherapy of Human Cancer. Edited by . New York: Elsevier-North Holland1982: 309. sect. 7. Google Scholar 4 : A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. New Engl. J. Med.1991; 325: 1205. Google Scholar 5 : Long-term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology1991; 38: 507. Google Scholar 6 : Intravesical therapy. A critical overview. Urol. Clin. N. Amer.1987; 14: 399. Google Scholar 7 : Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J. Urol.1984; 132: 27. Link, Google Scholar 8 : Role of intravesical mitomycin C in management of superficial bladder tumors. Urology1980; 16: 11. Google Scholar 9 : Evaluation and management of patients with superficial bladder cancer. Urol. Clin. N. Amer.1987; 14: 771. Google Scholar 10 : BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. Urology1988; 31: 20. Google Scholar 11 : Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J. Urol.1985; 134: 48. Link, Google Scholar 12 : Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res.1987; 47: 1762. Google Scholar 13 : Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J. Urol.1988; 139: 410. Link, Google Scholar 14 : TNM Classification of Malignant Tumours. Heidelberg: Springer-Verlag1987. Google Scholar 15 : Tumors of the urinary bladder. Atlas of Tumor Pathology, 2nd series. Washington, D. C.: Armed Forces Institute of Pathology1975. fasc. 11. Google Scholar 16 : A randomized prospective study comparing intravesical instillations of Mitomycin-C, BCG-Tice and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Eur. J. Cancer1993; 29A: 1672. Google Scholar 17 : Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. N. Amer.1992; 19: 573. Google Scholar 18 : Long-term effect of intravesical bacillus Calmette-Guerin (BCG) Tice strain on flat carcinoma in situ of the bladder. Prog. Clin. Biol. Res.1989; 310: 171. Google Scholar 19 : A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J. Clin. Oncol.1987; 5: 441. Google Scholar 20 : Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J. Urol.1987; 138: 295. Link, Google Scholar 21 : SWOG 8795: a randomized comparison of bacillus Calmette Guerin and mitomycin C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. J. Urol.1993; 149: 282A. part 2, abstract 275. Google Scholar From the Department of Urology, Rijnland Hospital, Leiderdorp, Bosch Medical Centre, Hertogenbosch, and Departments of Urology and Medical Statistics, University Hospital, Nijmegen, The Netherlands. Division of Urology, University of Colorado, Denver, Colorado.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byYu D, Lee C and Chang S (2018) Immunotherapy for Orthotopic Murine Bladder Cancer Using Bacillus Calmette-Guerin Recombinant Protein Mpt-64Journal of Urology, VOL. 177, NO. 2, (738-742), Online publication date: 1-Feb-2007.SYLVESTER R, van der MEIJDEN A, WITJES J and KURTH K (2018) BACILLUS CALMETTE-GUERIN VERSUS CHEMOTHERAPY FOR THE INTRAVESICAL TREATMENT OF PATIENTS WITH CARCINOMA IN SITU OF THE BLADDER: A META-ANALYSIS OF THE PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology, VOL. 174, NO. 1, (86-91), Online publication date: 1-Jul-2005.LEE C, CHANG S, HSIEH D and YU D (2018) Immunotherapy for Bladder Cancer Using Recombinant Bacillus Calmette-Guerin DNA Vaccines and Interleukin-12 DNA VaccineJournal of Urology, VOL. 171, NO. 3, (1343-1347), Online publication date: 1-Mar-2004.BÖHLE A, JOCHAM D and BOCK P (2018) Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and ToxicityJournal of Urology, VOL. 169, NO. 1, (90-95), Online publication date: 1-Jan-2003.SYLVESTER R, van der MEIJDEN A and LAMM D (2018) Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, VOL. 168, NO. 5, (1964-1970), Online publication date: 1-Nov-2002.KAASINEN E, RINTALA E, PERE A, KALLIO J, PUOLAKKA V, LIUKKONEN T and TUHKANEN K (2018) WEEKLY MITOMYCIN C FOLLOWED BY MONTHLY BACILLUS CALMETTE-GUERIN OR ALTERNATING MONTHLY INTERFERON-α2B AND BACILLUS CALMETTE-GUERIN FOR PROPHYLAXIS OF RECURRENT PAPILLARY SUPERFICIAL BLADDER CARCINOMAJournal of Urology, VOL. 164, NO. 1, (47-52), Online publication date: 1-Jul-2000.LEBRET T, BOHIN D, KASSARDJIAN Z, HERVE J, MOLINIE V, BARRE P, LUGAGNE P and BOTTO H (2018) RECURRENCE, PROGRESSION AND SUCCESS IN STAGE TA GRADE 3 BLADDER TUMORS TREATED WITH LOW DOSE BACILLUS CALMETTE-GUERIN INSTILLATIONSJournal of Urology, VOL. 163, NO. 1, (63-67), Online publication date: 1-Jan-2000.LOSA A, HURLE R and LEMBO A (2018) LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER: LONG-TERM RESULTSJournal of Urology, VOL. 163, NO. 1, (68-72), Online publication date: 1-Jan-2000.de REIJKE T, de BOER E, KURTH K and SCHAMHART D (2018) URINARY INTERLEUKIN-2 MONITORING DURING PROLONGED BACILLUS CALMETTE-GUERIN TREATMENT: CAN IT PREDICT THE OPTIMAL NUMBER OF INSTILLATIONS?Journal of Urology, VOL. 161, NO. 1, (67-71), Online publication date: 1-Jan-1999.MALMSTROM P, WIJKSTROM H, LUNDHOLM C, WESTER K, BUSCH C and NORLEN B (2018) 5-YEAR FOLLOWUP OF A RANDOMIZED PROSPECTIVE STUDY COMPARING MITOMYCIN C AND BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER CARCINOMAJournal of Urology, VOL. 161, NO. 4, (1124-1127), Online publication date: 1-Apr-1999.ALI-EL-DEIN B, NABEEH A, ISMAIL E and GHONEIM M (2018) SEQUENTIAL BACILLUS CALMETTE-GUERIN AND EPIRUBICIN VERSUS BACILLUS CALMETTE-GUERIN ALONE FOR SUPERFICIAL BLADDER TUMORS: A RANDOMIZED PROSPECTIVE STUDYJournal of Urology, VOL. 162, NO. 2, (339-342), Online publication date: 1-Aug-1999.Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H and Marberger M (2018) DOES TOPICAL INSTILLATION THERAPY INFLUENCE CHROMOSOMAL ABERRATIONS IN SUPERFICIAL BLADDER CANCER?Journal of Urology, VOL. 159, NO. 1, (265-269), Online publication date: 1-Jan-1998.Stanisic T (2018) Editorial: New Data From Abroad About Intravesical Therapy of Bladder Cancer--How Does It Play in Peoria?Journal of Urology, VOL. 155, NO. 4, (1239-1240), Online publication date: 1-Apr-1996.Rintala E, Jauhiainen K, Kaasinen E, Nurmi M and Alfthan O (2018) Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Prophylaxis For Recurrent Papillary (Stages Ta to T1) Superficial Bladder CancerJournal of Urology, VOL. 156, NO. 1, (56-60), Online publication date: 1-Jul-1996.Lundholm C, Norlen B, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, Olsson J, Tveter K, Westberg R and Malmstrom P (2018) A Randomized Prospective Study Comparing Long-Term Intravesical Instillations of Mitomycin C and Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, VOL. 156, NO. 2, (372-376), Online publication date: 1-Aug-1996. Volume 153Issue 3SMarch 1995Page: 929-933 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information Peter D.J. Vegt More articles by this author J. Alfred Witjes More articles by this author Wim P.J. Witjes More articles by this author Wim H. Doesburg More articles by this author Frans M.J. Debruyne More articles by this author A.P.M. van der Meijden More articles by this author E. David Crawford More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2119010338 created "2016-06-24" @default.
• W2119010338 creator A5011379133 @default.
• W2119010338 creator A5014213335 @default.
• W2119010338 creator A5024919772 @default.
• W2119010338 creator A5030962499 @default.
• W2119010338 creator A5034329274 @default.
• W2119010338 creator A5035624288 @default.
• W2119010338 creator A5075711884 @default.
• W2119010338 date "1995-03-01" @default.
• W2119010338 modified "2023-10-14" @default.
• W2119010338 title "Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the Bladder" @default.
• W2119010338 cites W131067198 @default.
• W2119010338 cites W1536690700 @default.
• W2119010338 cites W1595735008 @default.
• W2119010338 cites W171038488 @default.
• W2119010338 cites W176965263 @default.
• W2119010338 cites W1974283005 @default.
• W2119010338 cites W2031107493 @default.
• W2119010338 cites W2074584619 @default.
• W2119010338 cites W2084090060 @default.
• W2119010338 cites W2147817958 @default.
• W2119010338 cites W2180705936 @default.
• W2119010338 cites W2333193688 @default.
• W2119010338 cites W2398843444 @default.
• W2119010338 cites W2405709561 @default.
• W2119010338 cites W2413038734 @default.
• W2119010338 cites W2413918639 @default.
• W2119010338 cites W2414572565 @default.
• W2119010338 cites W2416728688 @default.
• W2119010338 cites W2418118083 @default.
• W2119010338 cites W2910173709 @default.
• W2119010338 cites W421126146 @default.
• W2119010338 cites W562473934 @default.
• W2119010338 doi "https://doi.org/10.1016/s0022-5347(01)67606-7" @default.
• W2119010338 hasPublicationYear "1995" @default.
• W2119010338 type Work @default.
• W2119010338 sameAs 2119010338 @default.
• W2119010338 citedByCount "110" @default.
• W2119010338 countsByYear W21190103382013 @default.
• W2119010338 countsByYear W21190103382014 @default.
• W2119010338 countsByYear W21190103382015 @default.
• W2119010338 countsByYear W21190103382016 @default.
• W2119010338 countsByYear W21190103382017 @default.
• W2119010338 countsByYear W21190103382018 @default.
• W2119010338 countsByYear W21190103382019 @default.
• W2119010338 countsByYear W21190103382021 @default.
• W2119010338 countsByYear W21190103382022 @default.
• W2119010338 countsByYear W21190103382023 @default.
• W2119010338 crossrefType "journal-article" @default.
• W2119010338 hasAuthorship W2119010338A5011379133 @default.
• W2119010338 hasAuthorship W2119010338A5014213335 @default.
• W2119010338 hasAuthorship W2119010338A5024919772 @default.
• W2119010338 hasAuthorship W2119010338A5030962499 @default.
• W2119010338 hasAuthorship W2119010338A5034329274 @default.
• W2119010338 hasAuthorship W2119010338A5035624288 @default.
• W2119010338 hasAuthorship W2119010338A5075711884 @default.
• W2119010338 hasConcept C121608353 @default.
• W2119010338 hasConcept C126322002 @default.
• W2119010338 hasConcept C126894567 @default.
• W2119010338 hasConcept C141071460 @default.
• W2119010338 hasConcept C143998085 @default.
• W2119010338 hasConcept C2777546739 @default.
• W2119010338 hasConcept C2777661416 @default.
• W2119010338 hasConcept C2779150676 @default.
• W2119010338 hasConcept C2779338040 @default.
• W2119010338 hasConcept C2780352672 @default.
• W2119010338 hasConcept C71924100 @default.
• W2119010338 hasConcept C86803240 @default.
• W2119010338 hasConcept C89423630 @default.
• W2119010338 hasConceptScore W2119010338C121608353 @default.
• W2119010338 hasConceptScore W2119010338C126322002 @default.
• W2119010338 hasConceptScore W2119010338C126894567 @default.
• W2119010338 hasConceptScore W2119010338C141071460 @default.
• W2119010338 hasConceptScore W2119010338C143998085 @default.
• W2119010338 hasConceptScore W2119010338C2777546739 @default.
• W2119010338 hasConceptScore W2119010338C2777661416 @default.
• W2119010338 hasConceptScore W2119010338C2779150676 @default.
• W2119010338 hasConceptScore W2119010338C2779338040 @default.
• W2119010338 hasConceptScore W2119010338C2780352672 @default.
• W2119010338 hasConceptScore W2119010338C71924100 @default.
• W2119010338 hasConceptScore W2119010338C86803240 @default.
• W2119010338 hasConceptScore W2119010338C89423630 @default.
• W2119010338 hasIssue "3S" @default.
• W2119010338 hasLocation W21190103381 @default.
• W2119010338 hasOpenAccess W2119010338 @default.
• W2119010338 hasPrimaryLocation W21190103381 @default.
• W2119010338 hasRelatedWork W1586830405 @default.
• W2119010338 hasRelatedWork W1972326352 @default.
• W2119010338 hasRelatedWork W2384311157 @default.
• W2119010338 hasRelatedWork W2433727248 @default.
• W2119010338 hasRelatedWork W2771908915 @default.
• W2119010338 hasRelatedWork W2795637274 @default.
• W2119010338 hasRelatedWork W4281756357 @default.
• W2119010338 hasRelatedWork W4303057512 @default.
• W2119010338 hasRelatedWork W4313197990 @default.
• W2119010338 hasRelatedWork W2118673085 @default.
• W2119010338 hasVolume "153" @default.

• next